2. Academic Validation
  3. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody

  • J Virol. 2013 Dec;87(24):13892-9. doi: 10.1128/JVI.02448-13.
Kei Ohnuma 1,  Bart L Haagmans,  Ryo Hatano,  V Stalin Raj,  Huihui Mou,  Satoshi Iwata,  Nam H Dang,  Berend Jan Bosch,  Chikao Morimoto
Affiliations

Affiliation

  • 1 Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Hongo, Bunkyo-ku, Tokyo, Japan.
PMID: 24067970 DOI: 10.1128/JVI.02448-13
Abstract

We identified the domains of CD26 involved in the binding of Middle East respiratory syndrome coronavirus (MERS-CoV) using distinct clones of anti-CD26 monoclonal antibodies (MAbs). One clone, named 2F9, almost completely inhibited viral entry. The humanized anti-CD26 MAb YS110 also significantly inhibited Infection. These findings indicate that both 2F9 and YS110 are potential therapeutic agents for MERS-CoV Infection. YS110, in particular, is a good candidate for immediate testing as a therapeutic modality for MERS.

Figures
Products